Determining the temporal, dose, and composition effects of nutritional substrates in an in vitro model of intrahepatocellular triglyceride accumulation.
in vitro
liver
metabolism
saturated fatty acids
Journal
Physiological reports
ISSN: 2051-817X
Titre abrégé: Physiol Rep
Pays: United States
ID NLM: 101607800
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
29
07
2022
received:
08
04
2022
accepted:
24
08
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
1
11
2022
Statut:
ppublish
Résumé
Pathological accumulation of intrahepatic triglyceride underpins the early stages of nonalcoholic fatty liver disease (NAFLD) and can progress to fibrosis, cirrhosis, and cancer of the liver. Studies in humans suggest that consumption of a diet enriched in saturated compared to unsaturated fatty acids (FAs), is more detrimental to liver fat accumulation and metabolism. However, the reasons for the divergence remain unclear and physiologically-relevant cellular models are required. Therefore, the aims of this study were to investigate the effect of modifying media composition, concentration, and treatment frequency of sugars, FAs and insulin on intrahepatocellular triglyceride content and intracellular glucose, FA and circadian function. Huh7 cells were treated with 2% human serum and a combination of sugars and FAs (low fat low sugar [LFLS], high fat low sugar [HFLS], or high fat high sugar [HFHS]) enriched in either unsaturated (OPLA) or saturated (POLA) FAs for 2, 4, or 7 days with a daily or alternating treatment regime. Stable isotope tracers were utilized to investigate basal and/or insulin-responsive changes in hepatocyte metabolism in response to different treatment regimes. Cell viability, media biochemistry, intracellular metabolism, and circadian biology were quantified. The FA composition of the media (OPLA vs. POLA) did not influence cell viability or intracellular triglyceride content in hepatocytes. In contrast, POLA-treated cells had lower FA oxidation and media acetate, and with higher FA concentrations, displayed lower intracellular glycogen content and diminished insulin stimulation of glycogenesis, compared to OPLA-treated cells. The addition of HFHS also had profound effects on circadian oscillation and gene expression. Cells treated daily with HFHS for at least 4 days resulted in a cellular model displaying characteristics of early stage NAFLD seen in humans. Repeated treatment for longer durations (≥7 days) may provide opportunities to investigate lipid and glucose metabolism in more severe stages of NAFLD.
Identifiants
pubmed: 36301719
doi: 10.14814/phy2.15463
pmc: PMC9612139
doi:
Substances chimiques
Triglycerides
0
Glucose
IY9XDZ35W2
Insulin
0
Fatty Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15463Subventions
Organisme : BHF Centre of Research Excellence, Oxford
ID : RE/18/3/34214
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R012512/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/F/000PR10347
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/15/56/31645
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/SBSRF/21/31013
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.
Références
J Clin Endocrinol Metab. 2019 Dec 1;104(12):6207-6219
pubmed: 31369090
Physiol Rep. 2017 Dec;5(24):
pubmed: 29263118
PLoS One. 2019 Dec 5;14(12):e0225604
pubmed: 31805072
Gastroenterology. 2008 Feb;134(2):424-31
pubmed: 18242210
Compr Physiol. 2014 Jan;4(1):177-97
pubmed: 24692138
Hepatology. 2013 Dec;58(6):1907-17
pubmed: 23775894
Biochem Biophys Res Commun. 2002 Sep 13;297(1):134-7
pubmed: 12220520
PLoS One. 2015 Jun 15;10(6):e0130047
pubmed: 26075729
Int J Mol Sci. 2021 Sep 10;22(18):
pubmed: 34575980
J Gastroenterol Hepatol. 2009 May;24(5):830-40
pubmed: 19207680
Nat Rev Gastroenterol Hepatol. 2021 Nov;18(11):770-786
pubmed: 34257427
Front Nutr. 2021 Nov 12;8:775382
pubmed: 34869541
Am J Physiol Endocrinol Metab. 2019 Apr 1;316(4):E578-E589
pubmed: 30694691
Physiol Rep. 2022 Oct;10(20):e15463
pubmed: 36301719
Clin Nutr. 2021 Mar;40(3):1108-1114
pubmed: 32753348
Physiol Rep. 2020 Jul;8(13):e14482
pubmed: 32643289
Redox Biol. 2014 Jan 09;2:457-65
pubmed: 24624335
Chem Biol Interact. 2007 Jan 30;165(2):106-16
pubmed: 17188672
Diabetes. 1996 Jul;45 Suppl 3:S24-6
pubmed: 8674884
Diabetes Care. 1996 Apr;19(4):390-3
pubmed: 8729170
J Biol Chem. 2010 Sep 24;285(39):29965-73
pubmed: 20647313
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Nat Metab. 2020 Dec;2(12):1369-1372
pubmed: 33046912
J Pharmacol Exp Ther. 2011 Nov;339(2):487-98
pubmed: 21856859
Lipids Health Dis. 2017 Oct 3;16(1):191
pubmed: 28974242
Am J Physiol Endocrinol Metab. 2002 Jul;283(1):E12-9
pubmed: 12067837
J Biol Chem. 1957 May;226(1):497-509
pubmed: 13428781
Clin Chim Acta. 2007 Jul;382(1-2):25-30
pubmed: 17442290
Physiol Res. 2015;64(Suppl 5):S627-36
pubmed: 26674288
Clin Exp Pharmacol Physiol. 2019 Dec;46(12):1101-1110
pubmed: 31397492
Am J Physiol Endocrinol Metab. 2010 Oct;299(4):E584-92
pubmed: 20628024
Br J Nutr. 2000 Nov;84(5):781-7
pubmed: 11177194
J Biol Chem. 2006 Apr 28;281(17):12093-101
pubmed: 16505490
Cell. 2013 Dec 19;155(7):1464-78
pubmed: 24360271
Gastroenterology. 2014 Mar;146(3):726-35
pubmed: 24316260
J Hepatol. 2016 May;64(5):1167-1175
pubmed: 26780287
Arch Biochem Biophys. 2015 Jan 15;566:26-35
pubmed: 25527164
Diabetes Care. 2018 Aug;41(8):1732-1739
pubmed: 29844096
Diabetes. 2016 Jul;65(7):1858-67
pubmed: 27207513
J Nutr Metab. 2013;2013:514206
pubmed: 23691291
Curr Opin Lipidol. 2011 Jun;22(3):216-24
pubmed: 21494141
Gastroenterology. 2020 May;158(7):1851-1864
pubmed: 32061595
Chronobiol Int. 2021 May;38(5):762-778
pubmed: 33612041
Food Chem Toxicol. 2020 Apr;138:111188
pubmed: 32045649
J Biol Chem. 1989 Jun 25;264(18):10347-50
pubmed: 2732225
Diabetes. 2014 Jul;63(7):2356-68
pubmed: 24550191
J Cell Biol. 2016 Oct 10;215(1):15-25
pubmed: 27738003
Mol Med Rep. 2014 Dec;10(6):3254-60
pubmed: 25241938
Adv Nutr. 2013 Nov 06;4(6):697-710
pubmed: 24228201
Am J Clin Nutr. 2012 May;95(5):1003-12
pubmed: 22492369
Eur J Clin Invest. 2007 Oct;37(10):774-82
pubmed: 17888088
Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Jun;1863(6):549-562
pubmed: 29501626